Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2000

01-09-2000 | Adis New Drug Profile

Nateglinide

A Viewpoint by Riccardo Perfetti

Author: Riccardo Perfetti

Published in: Drugs | Issue 3/2000

Login to get access

Excerpt

The onset of type 2 diabetes is characterised by 2 determining factors: insufficient ability to secrete insulin and/or resistance to its biological action.[1] Current biomedical research continues to clarify the relative contributions of these defects to the pathogenesis of type 2 diabetes, and novel pharmacological agents are designed specifically to correct either the impaired insulin secretory activity or the resistance to the action of insulin. …
Literature
1.
Polonsky KS. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S124–7PubMedCrossRef
2.
Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabetic Med 1996; 13 Suppl. 6: S151–5PubMed
3.
Akiyoshi M, Kakei M, Nakazaki M. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 1995; 268 (2 pt 1): E185–93PubMed
4.
Ikenoue T, Okazaki K, Fujitani S, et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclo-hexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and gliben-clamide. Biol Pharm Bull 1997; 20(4): 354–9PubMedCrossRef
5.
Ikenoue T, Akiyoshi M, Fujitani S, et al. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). BrJPharmacol 1997; 120: 137–45
6.
Sato Y, Nishikawa M, Shinkai H, et al. Possibility of ideal blood glucose control by a new oral hypoglycaemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991; 12(1): 53–9PubMedCrossRef
7.
Kalbag J, Hirschberg Y, McLeod JE Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: A106CrossRef
8.
Bloomgarden ZT. New and traditional treatment of glycemia in NIDDM. Diabetes Care 1996; 19(3): 295–9PubMed
9.
Hirschberg Y, McLeod J, Garreffa S. Pharmacodynamics and dose response of nateglinide in type 2 diabetics [abstract]. Diabetes 1999 May; 48 Suppl. 1: A100
Metadata
Title
Nateglinide
A Viewpoint by Riccardo Perfetti
Author
Riccardo Perfetti
Publication date
01-09-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200060030-00008

Other articles of this Issue 3/2000

Drugs 3/2000 Go to the issue

Adis Drug Evaluation

Desirudin

Adis Drug Evaluation

Meropenem

Adis New Drug Profile

Nateglinide

Review Article

Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism

Leading Article

Immune Tolerance Therapy for Haemophilia

Leading Article

Combination Chemotherapy for Hepatitis B Virus